UK NICE set for U-turn on Lucentis
The UK National Institute for Health and Clinical Excellence (NICE), which gives guidance on the use of medicines in the National Health Service for England and Wales, is about to do a U-turn over drugs for age-related macular degeneration, according to a report in the Daily Telegraph newspaper. This stated that the NICE, on December 14 (after this issue went to press), would abolish its "second eye" stipulation for the use of Novartis' Lucentis (ranibizumab; Marketletters passim).
Court allows NICE challenge on AD drugs
Meantime, the UK Court of Appeal has granted permission for Eisai and Pfizer to appeal the High Court ruling on the NICE's decision regarding their Alzheimer's disease drug Aricept (donepezil; Marketletter August 20).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze